Skip to main content
. 2019 Nov 21;9:17309. doi: 10.1038/s41598-019-54032-1

Figure 3.

Figure 3

CSF GAP-43 at baseline and after DMTs: CSF GAP-43 concentrations at baseline and follow-up after fingolimod (A) and alemtuzumab (B) treatment. CSF, cerebrospinal fluid; GAP-43, growth-associated protein 43; DMTs, disease-modifying therapies.